Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet’s UroGen Pharma URGN Stock Holding History

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,823	Closed	-$392K	–	81
2026 Q1	$392K	Hold	21,823	–	–	0.08%	57
2025 Q4	$511K	Hold	21,823	–	–	0.1%	59
2025 Q3	$434K	Hold	21,823	–	–	0.09%	59
2025 Q2	$299K	Hold	21,823	–	–	0.07%	59
2025 Q1	$241K	Hold	21,823	–	–	0.06%	63
2024 Q4	$232K	Hold	21,823	–	–	0.06%	59
2024 Q3	$277K	Hold	21,823	–	–	0.07%	58
2024 Q2	$366K	Hold	21,823	–	–	0.1%	57
2024 Q1	$327K	Hold	21,823	–	–	0.09%	59
2023 Q4	$327K	Hold	21,823	–	–	0.06%	79
2023 Q3	$314K	Hold	21,823	–	–	0.07%	81
2023 Q2	$235K	Hold	21,823	–	–	0.05%	83
2023 Q1	$183K	Hold	21,823	–	–	0.04%	85
2022 Q4	$183K	Hold	21,823	–	–	0.04%	87
2022 Q3	$179K	Hold	21,823	–	–	0.04%	88
2022 Q2	$177K	Hold	21,823	–	–	0.04%	87
2022 Q1	$189K	Hold	21,823	–	–	0.03%	85
2021 Q4	$208K	Hold	21,823	–	–	0.03%	87
2021 Q3	$367K	Hold	21,823	–	–	0.07%	84
2021 Q2	$333K	Hold	21,823	–	–	0.06%	83
2021 Q1	$425K	Hold	21,823	–	–	0.09%	75
2020 Q4	$393K	Buy	+21,823	New	+$457K	0.09%	73

Other funds holding URGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet's URGN Position: Q2 2026 in Review

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 21,823 shares — an estimated $392K sold.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet first reported a position in URGN in Q4 2020 and held it in 22 quarters. The position peaked at $511K in Q4 2025. 90 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet sold 21,823 UroGen Pharma shares in Q2 2026, an estimated $392K.
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet first reported a position in UroGen Pharma in Q4 2020 and held it in 22 quarters.
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet's UroGen Pharma position peaked at $511K in Q4 2025.
90 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet's 13F filing for Q2 2026, filed 5 Aug 2026.